Form 4: IDEAYA Biosciences CEO Yujiro Hata Executes Stock Option and Sells Shares Under 10b5-1 Plan

IDEAYA Biosciences CEO Yujiro Hata exercised stock options and sold shares of common stock between May 14 and May 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Yujiro Hata, the President and CEO of IDEAYA Biosciences, Inc., executed stock options and sold shares of common stock between May 14 and May 16, 2024.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on December 22, 2023.
• On May 14, 2024, Hata exercised options to acquire 56,711 shares at a price of $4.31 per share and sold 56,711 shares in multiple trades at a weighted average price of $41.6011.
• Also on May 14, 2024, Hata sold 2,303 shares in multiple trades at a weighted average price of $41.8357.
• On May 15, 2024, Hata exercised options to acquire 83,856 shares at a price of $4.31 per share and sold 83,856 shares in multiple trades at weighted average prices of $42.5741, $43.4775 and $44.1179.
• On May 16, 2024, Hata exercised options to acquire 34,433 shares at a price of $4.31 per share and sold 34,433 shares in multiple trades at weighted average prices of $41.7333 and $42.366.
• Following these transactions, Hata directly owns 677,887 shares of IDEAYA Biosciences common stock.
• Hata also holds options to purchase 49,454 shares of common stock at an exercise price of $4.31, exercisable until February 26, 2028.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of insider trading activity. The transactions were pre-planned and do not necessarily indicate a positive or negative outlook on the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions and is common for publicly traded companies. The use of a 10b5-1 trading plan allows insiders to sell shares over a period of time without being accused of trading on non-public information.

Comparison to Industry Standards

• Insider selling is a common occurrence in publicly traded companies, particularly in the biotechnology sector where stock options are a significant part of executive compensation.
• The use of a 10b5-1 trading plan is a standard practice to avoid accusations of illegal insider trading.
• Comparable companies such as Relay Therapeutics, Black Diamond Therapeutics, and Blueprint Medicines also see regular Form 4 filings from their executives.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.
• However, the pre-planned nature of the sales mitigates concerns about insider information being used for personal gain.

Key Dates